Alcobra (ADHD) Issued New US Patent Covering Metadoxine Use For Cognitive Disorders
5/1/2014 9:36:27 AM
TEL AVIV, Israel, May 1, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that the United States Patent and Trademark Office ("USPTO") has issued a new patent covering MDX's use in the treatment of Cognitive Disorders.
Help employers find you! Check out all the jobs and post your resume.
comments powered by